Does chemoradiotherapy improve outcomes for surgically resected adenocarcinoma of the stomach or esophagus?

Naveenraj L. Solomon, Michael C. Cheung, Margaret M. Byrne, Ying Zhuge, Dido Franceschi, Alan S. Livingstone, Leonidas Koniaris

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Background: To use a population-based registry to evaluate the effect of chemotherapy or radiation on survival for patients undergoing curative-intent surgery for adenocarcinoma of the esophagus or stomach. Methods: A linked data set between the Florida Cancer Data System and the Florida Agency for Health Care Administration from 1998 to 2003 was queried. Results: Overall, 3,378 patients underwent surgical extirpation with curative intent, 636 patients had esophageal adenocarcinoma (EAC), and 2,742 patients had gastric adenocarcinoma (GAC). Outcomes were adjusted for patient comorbidities and hospital teaching status. Overall, no benefit was observed for adjuvant therapies for EAC patients. A small improvement in survival was observed with adjuvant therapies for GAC. For localized EAC or GAC there was no additional survival benefit associated with adjuvant therapies. For patients with regional EAC, chemotherapy (20.0 vs. 13.0 months, P <.001) and radiation (18.6 vs. 13.5 months, P = .007) were associated with a statistically significant survival benefit. In multivariate analysis, independent predictors of improved survival for regional EAC include chemotherapy (hazard ratio [HR] .535, P <.001) and radiotherapy (HR .656, P = .01). For GAC, patients with regional disease showed an improved median survival with chemotherapy (21.1 vs. 11.2 months, P <.001) and radiotherapy (22.6 vs. 12.3 months, P <.001). In multivariate analysis, independent predictors of improved survival for regional GAC include chemotherapy (HR .629, P <.001) and radiation (HR .603, P <.001). Conclusions: Patients with regional adenocarcinoma of the esophagus or stomach, but not those with localized disease, derive a statistically significant survival benefit from the addition of chemotherapy and radiation to surgical resection.

Original languageEnglish (US)
Pages (from-to)98-108
Number of pages11
JournalAnnals of Surgical Oncology
Volume17
Issue number1
DOIs
StatePublished - Jan 2010
Externally publishedYes

Fingerprint

Chemoradiotherapy
Esophagus
Stomach
Adenocarcinoma
Survival
Drug Therapy
Radiation
Radiotherapy
Multivariate Analysis
Information Systems
Teaching Hospitals
Registries
Comorbidity
Therapeutics
Delivery of Health Care

ASJC Scopus subject areas

  • Surgery
  • Oncology

Cite this

Does chemoradiotherapy improve outcomes for surgically resected adenocarcinoma of the stomach or esophagus? / Solomon, Naveenraj L.; Cheung, Michael C.; Byrne, Margaret M.; Zhuge, Ying; Franceschi, Dido; Livingstone, Alan S.; Koniaris, Leonidas.

In: Annals of Surgical Oncology, Vol. 17, No. 1, 01.2010, p. 98-108.

Research output: Contribution to journalArticle

Solomon, Naveenraj L. ; Cheung, Michael C. ; Byrne, Margaret M. ; Zhuge, Ying ; Franceschi, Dido ; Livingstone, Alan S. ; Koniaris, Leonidas. / Does chemoradiotherapy improve outcomes for surgically resected adenocarcinoma of the stomach or esophagus?. In: Annals of Surgical Oncology. 2010 ; Vol. 17, No. 1. pp. 98-108.
@article{cc34672f18e844d1993c23faf73b7c1d,
title = "Does chemoradiotherapy improve outcomes for surgically resected adenocarcinoma of the stomach or esophagus?",
abstract = "Background: To use a population-based registry to evaluate the effect of chemotherapy or radiation on survival for patients undergoing curative-intent surgery for adenocarcinoma of the esophagus or stomach. Methods: A linked data set between the Florida Cancer Data System and the Florida Agency for Health Care Administration from 1998 to 2003 was queried. Results: Overall, 3,378 patients underwent surgical extirpation with curative intent, 636 patients had esophageal adenocarcinoma (EAC), and 2,742 patients had gastric adenocarcinoma (GAC). Outcomes were adjusted for patient comorbidities and hospital teaching status. Overall, no benefit was observed for adjuvant therapies for EAC patients. A small improvement in survival was observed with adjuvant therapies for GAC. For localized EAC or GAC there was no additional survival benefit associated with adjuvant therapies. For patients with regional EAC, chemotherapy (20.0 vs. 13.0 months, P <.001) and radiation (18.6 vs. 13.5 months, P = .007) were associated with a statistically significant survival benefit. In multivariate analysis, independent predictors of improved survival for regional EAC include chemotherapy (hazard ratio [HR] .535, P <.001) and radiotherapy (HR .656, P = .01). For GAC, patients with regional disease showed an improved median survival with chemotherapy (21.1 vs. 11.2 months, P <.001) and radiotherapy (22.6 vs. 12.3 months, P <.001). In multivariate analysis, independent predictors of improved survival for regional GAC include chemotherapy (HR .629, P <.001) and radiation (HR .603, P <.001). Conclusions: Patients with regional adenocarcinoma of the esophagus or stomach, but not those with localized disease, derive a statistically significant survival benefit from the addition of chemotherapy and radiation to surgical resection.",
author = "Solomon, {Naveenraj L.} and Cheung, {Michael C.} and Byrne, {Margaret M.} and Ying Zhuge and Dido Franceschi and Livingstone, {Alan S.} and Leonidas Koniaris",
year = "2010",
month = "1",
doi = "10.1245/s10434-009-0679-y",
language = "English (US)",
volume = "17",
pages = "98--108",
journal = "Annals of Surgical Oncology",
issn = "1068-9265",
publisher = "Springer New York",
number = "1",

}

TY - JOUR

T1 - Does chemoradiotherapy improve outcomes for surgically resected adenocarcinoma of the stomach or esophagus?

AU - Solomon, Naveenraj L.

AU - Cheung, Michael C.

AU - Byrne, Margaret M.

AU - Zhuge, Ying

AU - Franceschi, Dido

AU - Livingstone, Alan S.

AU - Koniaris, Leonidas

PY - 2010/1

Y1 - 2010/1

N2 - Background: To use a population-based registry to evaluate the effect of chemotherapy or radiation on survival for patients undergoing curative-intent surgery for adenocarcinoma of the esophagus or stomach. Methods: A linked data set between the Florida Cancer Data System and the Florida Agency for Health Care Administration from 1998 to 2003 was queried. Results: Overall, 3,378 patients underwent surgical extirpation with curative intent, 636 patients had esophageal adenocarcinoma (EAC), and 2,742 patients had gastric adenocarcinoma (GAC). Outcomes were adjusted for patient comorbidities and hospital teaching status. Overall, no benefit was observed for adjuvant therapies for EAC patients. A small improvement in survival was observed with adjuvant therapies for GAC. For localized EAC or GAC there was no additional survival benefit associated with adjuvant therapies. For patients with regional EAC, chemotherapy (20.0 vs. 13.0 months, P <.001) and radiation (18.6 vs. 13.5 months, P = .007) were associated with a statistically significant survival benefit. In multivariate analysis, independent predictors of improved survival for regional EAC include chemotherapy (hazard ratio [HR] .535, P <.001) and radiotherapy (HR .656, P = .01). For GAC, patients with regional disease showed an improved median survival with chemotherapy (21.1 vs. 11.2 months, P <.001) and radiotherapy (22.6 vs. 12.3 months, P <.001). In multivariate analysis, independent predictors of improved survival for regional GAC include chemotherapy (HR .629, P <.001) and radiation (HR .603, P <.001). Conclusions: Patients with regional adenocarcinoma of the esophagus or stomach, but not those with localized disease, derive a statistically significant survival benefit from the addition of chemotherapy and radiation to surgical resection.

AB - Background: To use a population-based registry to evaluate the effect of chemotherapy or radiation on survival for patients undergoing curative-intent surgery for adenocarcinoma of the esophagus or stomach. Methods: A linked data set between the Florida Cancer Data System and the Florida Agency for Health Care Administration from 1998 to 2003 was queried. Results: Overall, 3,378 patients underwent surgical extirpation with curative intent, 636 patients had esophageal adenocarcinoma (EAC), and 2,742 patients had gastric adenocarcinoma (GAC). Outcomes were adjusted for patient comorbidities and hospital teaching status. Overall, no benefit was observed for adjuvant therapies for EAC patients. A small improvement in survival was observed with adjuvant therapies for GAC. For localized EAC or GAC there was no additional survival benefit associated with adjuvant therapies. For patients with regional EAC, chemotherapy (20.0 vs. 13.0 months, P <.001) and radiation (18.6 vs. 13.5 months, P = .007) were associated with a statistically significant survival benefit. In multivariate analysis, independent predictors of improved survival for regional EAC include chemotherapy (hazard ratio [HR] .535, P <.001) and radiotherapy (HR .656, P = .01). For GAC, patients with regional disease showed an improved median survival with chemotherapy (21.1 vs. 11.2 months, P <.001) and radiotherapy (22.6 vs. 12.3 months, P <.001). In multivariate analysis, independent predictors of improved survival for regional GAC include chemotherapy (HR .629, P <.001) and radiation (HR .603, P <.001). Conclusions: Patients with regional adenocarcinoma of the esophagus or stomach, but not those with localized disease, derive a statistically significant survival benefit from the addition of chemotherapy and radiation to surgical resection.

UR - http://www.scopus.com/inward/record.url?scp=74649087202&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=74649087202&partnerID=8YFLogxK

U2 - 10.1245/s10434-009-0679-y

DO - 10.1245/s10434-009-0679-y

M3 - Article

C2 - 19777191

AN - SCOPUS:74649087202

VL - 17

SP - 98

EP - 108

JO - Annals of Surgical Oncology

JF - Annals of Surgical Oncology

SN - 1068-9265

IS - 1

ER -